Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy
(WorldNews Germany)

FOR IMMEDIATE RELEASE Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy Heidelberg, Germany, April 16, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today presented a poster entitled "Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors" in the "Therapeutic Antibodies, Including Engineered Antibodies 2" session at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago. Despite several marketed...